Entinostat

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Entinostat ( , , ), sold under the brand name Jingzhuda and also known by its developmental code names SNDX-275 and MS-275, is a histone deacetylase (HDAC) inhibitor which is used in the treatment of HER2-negative breast cancer. It is also under development for the treatment of HER2-positive breast cancer and was previously under development for a large number of other cancers. The drug is taken orally.

Entinostat ( , , ), sold under the brand name Jingzhuda and also known by its developmental code names SNDX-275 and MS-275, is a histone deacetylase (HDAC) inhibitor which is used in the treatment of HER2-negative breast cancer. It is also under development for the treatment of HER2-positive breast cancer and was previously under development for a large number of other cancers. The drug is taken orally.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1368798893 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

Extracted from the cited revision's reference blocks; absent citations are not invented.